Drug Profile

GENV HEM

Alternative Names: AAV8.FVa; GENV-HEM

Latest Information Update: 05 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of North Carolina
Developer GeneVentiv Therapeutics
Class Antihaemorrhagics; Gene therapies
Mechanism of Action Factor V replacements; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Haemophilia
New Molecular Entity No

Highest Development Phases

Preclinical Haemophilia

Most Recent Events

29 Oct 2025 GeneVentiv Therapeutics announces intention to submit IND application to regulatory body for Haemophilia in 2026
16 Apr 2024 GeneVentiv Therapeutics receives SBIR grant from the National Heart Lung Blood Institute (NHLBI) for GENV-HEM development in Haemophilia
13 Mar 2024 GeneVentiv announces intention to submit IND application to the US FDA for hemophilia

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com